Delving into the Latest Updates on Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) with Synapse

Overview

Basic Info

Drug Type

Inactivated vaccine, Combination vaccine, Prophylactic vaccine

+ [1]

Synonyms

Boostrix, dTpa vaccine, Refortrix

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory DiseasesOther Diseases

Active Indication

DiphtheriaTetanusWhooping Cough

Inactive Indication-

Originator Organization

GSK Plc

Active Organization

GlaxoSmithKline GmbH & Co. KG

GSK PlcGlaxoSmithKline LLC

Inactive Organization-

License Organization

GSK Plc

SK bioscience Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

Austria (03 Oct 2000),

DiphtheriaTetanusWhooping Cough

Regulation-

Login to view timeline

The goal of this clinical trial is to learn if the RSV vaccine (protects against respiratory syncytial virus) and Tdap vaccine (protects against pertussis) are most effective in pregnant individuals when taken together at the same visit, or separately at different visits. This clinical trial will also learn about the safety and immune responses of these vaccines in pregnancy.
The Main question:
-Is it possible to run a successful trial that tests how safe and effective it is to give Tdap and RSV vaccines in pregnancy either at the same time or one after the other, at different visits?
The Secondary question:
-To determine how safe and how well the Tdap and RSV vaccines work when given in pregnancy either at the same time or one after the other, at different visits.
The Exploratory (optional participation) questions:
* To measure the levels of antibodies against whooping cough (pertussis) and RSV in mothers at 7 and 19 months after giving birth, depending on whether they got the vaccines at the same time or one after the other during pregnancy.
* To measure whooping cough antibody levels in the babies at 2, 7, and 19 months of age, whose mothers who received the vaccines in pregnancy.
* To measure the levels of RSV antibodies in the mothers' breast milk at 1 week, 2 weeks, 4 weeks, and 2 months after giving birth.
Participants will be randomly assigned to Group 1 (vaccines given at the same time, same visit) or Group 2 (vaccines given one after the other, at different visits).
There are 4 visits as part of the main study, and 6 additional visits as part of the optional study (exploratory questions).
Visit 1-2: Blood collection and vaccines administered Visit 3-4: Blood work (cord blood sample collection from infant, after delivery, if possible) Visit 5-8: Breast milk collection Visit 8-10: Blood collection (infant blood collection only at Visit 8).
Participants will be asked to keep a diary of symptoms throughout the study.

Start Date16 Oct 2025

Sponsor / Collaborator

Canadian Immunization Research Network

[+6]

NCT06494475

/ Not yet recruitingPhase 2/3

A Randomised, Observer-Blind Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of a Group B Streptococcus Vaccine (GBS-NN/NN2) When 1 Dose is Administered Concomitantly With the Tdap Vaccine in Healthy-non Pregnant Women 18 to 49 Years of Age Compared to When Each Vaccine is Administered Alone

The main objectives of the study are to demonstrate the non-inferiority of the immune response induced by co administered GBS-NN/NN2 and tetanus, diphtheria, and acellular pertussis (Tdap) compared to the separate administration of GBS-NN/NN2 and Tdap, to evaluate the reactogenicity of GBS NN/NN2 when administered alone or in combination with Tdap, and to evaluate the safety of GBS-NN/NN2 when administered alone or in combination with Tdap in terms of serious adverse events (SAEs) and unsolicited adverse events (AEs).

Start Date17 Dec 2024

Sponsor / Collaborator

MinervaX ApS

NCT06015308

/ Active, not recruitingPhase 2

A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis

This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live vaccines in adult participants with moderate-to-severe atopic dermatitis (AD).
The purpose of this study is to compare the immune responses to concomitantly administered Boostrix (tetanus, diphtheria, and acellular pertussis [Tdap]) and Pneumovax 23 (PPSV) vaccines in adult participants with moderate-to-severe AD treated with amlitelimab versus placebo. The study will evaluate the percentage of participants achieving a positive anti-tetanus response at Week 16 (primary endpoint) and a positive anti-pneumococcal response at Week 16 (key secondary endpoint).
Study details include:
The study duration will be up to 36 weeks (for participants not entering the LTS17367 [RIVER-AD]).
The screening period will be 9 days to 4 weeks. The treatment duration will be up to 16 weeks. The post-treatment safety follow-up period will be16 weeks. The number of visits will be up to 7 (or 6 for those entering LTS17367 [RIVER-AD]).

Start Date06 Oct 2023

Sponsor / Collaborator

Sanofi

100 Clinical Results associated with Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc)

Login to view more data

100 Translational Medicine associated with Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc)

Login to view more data

100 Patents (Medical) associated with Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc)

Login to view more data

342

Literatures (Medical) associated with Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc)

31 Dec 2025·Human Vaccines & Immunotherapeutics

Economic evaluation of the second booster dose of diphtheria-tetanus-acellular pertussis vaccine for children aged 6 years in Zhejiang Province: A cost-utility analysis

Article

Author: Zheng, Shuhan ; Zhou, Yang ; Su, Ying ; He, Hanqing ; Zhu, Yao ; Tang, Xuewen ; Luo, Feng

Despite increasing pertussis breakthroughs and waning immunity, this study evaluates the cost-effectiveness of replacing the DT booster with DTaP in 6-year-olds in Zhejiang, China. While implemented in high-income regions, this strategy's cost-effectiveness remains unassessed in diverse Chinese settings. We address this gap using local data.Using surveillance data from the Zhejiang Provincial Center for Disease Control and Prevention, literature reviews, and a 10-year simulation timeframe, a decision tree-Markov model was constructed from a societal perspective. The study cohort was 6-year-old children in Zhejiang Province in 2022. Comprehensive evaluation indicators, including Incremental Cost Effectiveness Ratio (ICER) and Incremental Cost-Utility Ratio (ICUR), were used. Robustness was assessed via Deterministic Sensitivity Analysis (DSA) and Probabilistic Sensitivity Analysis (PSA). Simulating 10 years after implementing the DTaP strategy for 628,619 children in 2022, under lower background incidence, DTaP could prevent 1,886 pertussis cases, reduce costs by 1.7 billion CNY, and gain 0.09 QALYs (ICUR = 3,096.15 CNY/QALY). Under higher incidence, it could prevent 8,743 cases, reduce costs by 1.6 billion CNY, and gain 0.084 QALYs (ICUR = 3,081.86 CNY/QALY). Both ICUR values are significantly lower than Zhejiang's per capita GDP (118,496 CNY). Our findings indicate that administering a second booster dose of DTaP to 6-year-old children is cost-effective, particularly with high incidence of pertussis.

01 Sep 2025·Academic Pediatrics

Impact of Interventions to Improve Human Papillomavirus Vaccine Uptake on Other Vaccines Due: A Secondary Analysis of a Randomized Trial

Article

Author: St Sauver, Jennifer L ; MacLaughlin, Kathy L ; Jenkins, Gregory ; Jacobson, Robert M ; Zhu, Xuan ; Herrin, Jeph ; Finney Rutten, Lila J ; Griffin, Joan M

OBJECTIVE:

We sought to determine if our recent trial of human papillomavirus (HPV) vaccine uptake improved influenza, meningococcal ACWY, and tetanus-diphtheria-acellular pertussis (Tdap) vaccine uptake.

METHODS:

We conducted a secondary analysis of our 4-year factorial stepped-wedge cluster-randomized trial of 6 primary care practices affiliated with the Mayo Clinic. We restricted our analysis to those adolescents 11- to 12-years-old due for at least 1 of 3 vaccines in addition to HPV. Trial arms included 1) usual care, 2) mailed reminder-recall letters to parents of empaneled adolescents following their birthdays alerting parents to the need for HPV vaccination and other vaccines due, 3) monthly confidential audit-feedback reports to providers sent via intracampus mail comparing rates of HPV vaccination for that provider with others, and 4) both interventions. Outcomes included receipt of influenza, meningococcal ACWY, and Tdap vaccines during the study step.

RESULTS:

Among trial participants, 8698 adolescents were due for ≥1 dose HPV and at least 1 of the other vaccines. The parent reminder-recall resulted in a clinically and statistically significant increase in uptake of the other vaccines (odds ratios ranging from 1.44-1.86, all 95% confidence intervals above 1.13) as it did in combination with the provider audit-feedback. Provider audit-feedback alone had no statistically significant impact.

CONCLUSIONS:

The parent reminder-recall substantially improved uptake of all 3 vaccines, whereas the provider audit-feedback did not. This made sense as the reminder-recall treated all vaccines as equally recommended without a focus on the HPV vaccine due, while the audit-feedback only reported the provider's success with HPV vaccine uptake.

14 May 2025·Qatar medical journal

Whooping cough in the most vulnerable: A case series of pertussis in infants younger than three months in Qatar

Article

Author: Elhamidi, Mohammad ; Alesali, Mohammad

Background: Pertussis, a highly contagious disease, has made a resurgence following the easing of COVID-19 pandemic restrictions. Infants under three months old are particularly vulnerable due to their immature immune systems and lack of protective vaccination. Methods: This study presents a case series of four infants, aged one to three months, who initially presented with nonspecific respiratory symptoms at Alkhor Hospital between January and June 2024. Subsequent diagnostic testing confirmed pertussis in all four cases. It is noteworthy that all cases involved were previously healthy infants with no underlying health conditions. Additionally, none of the mothers had received the Tdap vaccine during pregnancy. Results: All infants required hospitalization, with one being admitted to the PICU for eight days. Ultimately, all four infants made a full recovery. Conclusion: Pertussis remains a significant cause of morbidity and mortality in infants under three months of age. Given the potential for severe complications and the burden it places on the healthcare system during outbreaks, it is crucial to emphasize preventive measures such as maternal vaccination.

16

News (Medical) associated with Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc)

08 Oct 2025

·www.prnewswire.com

Breathe Easy This Winter: New Campaign Urges Vaccination to Protect Against Seasonal Flu and Other Respiratory Illnesses

CHICAGO, Oct. 8, 2025 /PRNewswire/ -- Today, the American Lung Association launched a campaign to educate individuals about the importance of immunizations to protect against respiratory diseases. Vaccines are the best tool to help protect people from severe illness, hospitalization and even death from several illnesses, including influenza (flu); COVID-19; pneumococcal pneumonia; pertussis (whopping cough); and respiratory syncytial virus (RSV), especially for individuals at high risk for health complications. Millions of people in the United States get sick from respiratory illnesses each year, with some seasonal virus cases typically peaking from October through March. During the 2024-2025 respiratory virus season, it is estimated that there were up to 82 million cases of the flu alone, resulting in up to 37 million medical visits, up to 1.3 million hospitalizations, and between 127,000 and 130,000 deaths, according to Centers for Disease Control & Prevention (CDC) preliminary estimates. During the 2023-2024 respiratory season, the CDC reported that COVID-19 vaccination prevented 68,000 hospitalizations, 13,000 intensive care unit (ICU) admissions and 5,300 in-hospital deaths. "Immunization is especially important for older adults and individuals with certain health conditions who are at increased risk of severe illness, complications and hospitalization from these vaccine-preventable respiratory diseases," said Harold Wimmer, President and CEO of the American Lung Association. "Not getting vaccinated puts you, your family and your neighbors at risk for severe disease." Vaccines help prepare the body to defend itself from germs like viruses and bacteria. And immunity through vaccination is safer and often longer lasting than immunity you develop after you get sick (also known as "natural immunity") as you cannot predict the severity of illness and recovery needed from a disease. Older adults and individuals with certain health conditions are at increased risk of severe complications from respiratory diseases that are preventable through vaccination. An unvaccinated older adult faces a higher risk of hospitalization and even death from the flu, pneumococcal pneumonia, RSV or COVID-19. This is because, as people age, their immune system naturally weakens, making them more susceptible to infections. Also, older adults often have one or more underlying health conditions like asthma or other chronic lung disease, heart disease, diabetes, etc., which further increases their risk. Respiratory infections can worsen existing chronic conditions like chronic obstructive pulmonary disease (COPD), leading to decreased quality of life and prolonged recovery times. The Lung Association's new campaign is raising awareness on the importance of these five vaccinations to help protect adults against severe respiratory illness: Influenza(flu): Annual flu vaccination is recommended for everyone age 6 months and older, ideally in September/October though vaccination can continue throughout the season as the flu virus circulates. COVID-19: COVID-19 vaccination is recommended for everyone six months and older with shared clinical decision-making, which is a discussion between a patient or caregiver and their healthcare provider. RSV: Adults ages 50-74 who are at increased risk of severe RSV disease, and adults age 75 and older should receive a single vaccine if they have not received one previously; additional doses are not recommended. Pertussis (whooping cough): Tdap is a combination vaccine that provides protection against pertussis and is recommended for all adults. A Tdap vaccine can be given at any time of the year and is especially important for adults living with asthma or COPD, who are at higher risk for complications. Pneumococcal pneumonia: Pneumococcal vaccination is recommended for adults age 19-49 with certain chronic health conditions or risk factors and all adults age 50 and older. Pregnant women and individuals who are immunocompromised often have additional vaccination recommendations and should consult their healthcare provider to be sure they are up to date on their recommended vaccinations. Often, multiple vaccines can be administered in a single healthcare provider visit; ask your healthcare provider about what vaccines are recommended for you. For more information, contact the Lung Association's HelpLine at 1-800-LUNGUSA. To learn more about vaccines, visit Lung.org/vaccines. Support for this new campaign was provided by Sanofi. About the American Lung Association The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic imperatives: to defeat lung cancer; to champion clean air for all; to improve the quality of life for those with lung disease and their families; and to create a tobacco-free future. For more information about the American Lung Association, which has a 4-star rating from Charity Navigator and is a Platinum-Level GuideStar Member, call 1-800-LUNGUSA (1-800-586-4872) or visit: Lung.org. To support the work of the American Lung Association, find a local event at Lung.org/events or donate today at Lung.org/donate. CONTACT: Jill Dale | American Lung Association P: 312-940-7001 M: 720-438-8289E: [email protected] SOURCE American Lung Association WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

VaccineAHA

06 Jan 2025

·www.drugs.com

U.S. Whooping Cough Cases Surge

MONDAY, Jan. 6, 2025 -- Rates of whooping cough in the U.S. continue to climb, according to data from the US Centers for Disease Control (CDC). Over 32,000 cases reported have been reported as of mid-December -- about six times more than there were at this time last year, and more than there have been since 2014, according to CNN. Whooping cough, also known as pertussis, is a very contagious respiratory illness that spreads through bacteria in the air. It is common in the United States, with frequent outbreaks. Reported cases have been climbing for several months with about a quarter of all cases reported in Illinois, Indiana and other states in the Midwest. Pennsylvania has more reported cases compared to other states. Some states, such as Oregon, ticked a record high number of cases recently. For 2024, Oregon recorded the highest number of whooping cough cases since 1950, a news release stated. Typically, the infection starts with cold-like symptoms before a serious, full-body cough can develop. The name comes from the sound people make as they try to catch their breath between coughs. The coughing can last for several weeks or even months. Cases dropped during the pandemic, but according to the CDC, recent trends suggest that the U.S. is returning to pre-pandemic levels. Whooping cough can be serious for people of all ages, yet children younger than one year old are especially vulnerable because their immune systems are not fully developed. Prevention in the form of vaccination is the best way to protect against whooping cough, the CDC says; the agency recommends that children get the DTaP vaccine and adolescents and adults get the TDaP vaccine. Among children, vaccination rates for this infectious disease have fallen with only about 92% of kindergartners having gotten their DTaP vaccine for the 2023-2024 school year. Antibiotics can treat the infection, but they work best if it’s caught within the first few weeks. If you think you've been exposed to the respiratory illness, ask your doctor about preventive antibiotics. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Vaccine

06 Jan 2025

·www.drugs.com

Pertussis Cases Surging in the United States

MONDAY, Jan. 6, 2025 -- Rates of pertussis in the United States are surging, with more than 32,000 cases reported as of mid-December -- about six times more than at this time last year and more than have been reported since 2014 , according to data from the U.S. Centers for Disease Control and Prevention. Reported cases have been climbing for several months, CNN reports. About a quarter of all cases have been reported in Illinois, Indiana, and other states in the Midwest. Pennsylvania has more reported cases compared with other states. Some states, such as Oregon, ticked a record high number of cases recently. For 2024, Oregon recorded the highest number of pertussis cases since 1950, Oregon Public Broadcasting reported. Cases dropped during the pandemic, but, according to the CDC, recent trends suggest that the United States is returning to prepandemic levels. Prevention, in the form of vaccination, is the best way to protect against whooping cough, the CDC says; the agency recommends that children get the DTaP vaccine and adolescents and adults get the Tdap vaccine. Among children, vaccination rates have fallen; only about 92 percent of kindergartners had gotten their DTaP vaccine for the 2023–2024 school year. This is below the 95 percent federal target. More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Vaccine

100 Deals associated with Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07CA02	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diphtheria	Austria	GlaxoSmithKline GmbH & Co. KG	03 Oct 2000
Diphtheria	Belgium	GlaxoSmithKline GmbH & Co. KG	03 Oct 2000
Diphtheria	Bulgaria	GlaxoSmithKline GmbH & Co. KG	03 Oct 2000
Diphtheria	Croatia	GlaxoSmithKline GmbH & Co. KG	03 Oct 2000
Diphtheria	Cyprus	GlaxoSmithKline GmbH & Co. KG	03 Oct 2000
Diphtheria	Czechia	GlaxoSmithKline GmbH & Co. KG	03 Oct 2000
Diphtheria	Denmark	GlaxoSmithKline GmbH & Co. KG	03 Oct 2000
Diphtheria	Estonia	GlaxoSmithKline GmbH & Co. KG	03 Oct 2000
Diphtheria	Finland	GlaxoSmithKline GmbH & Co. KG	03 Oct 2000
Diphtheria	France	GlaxoSmithKline GmbH & Co. KG	03 Oct 2000
Diphtheria	Germany	GlaxoSmithKline GmbH & Co. KG	03 Oct 2000
Diphtheria	Greece	GlaxoSmithKline GmbH & Co. KG	03 Oct 2000
Diphtheria	Hungary	GlaxoSmithKline GmbH & Co. KG	03 Oct 2000
Diphtheria	Iceland	GlaxoSmithKline GmbH & Co. KG	03 Oct 2000
Diphtheria	Ireland	GlaxoSmithKline GmbH & Co. KG	03 Oct 2000
Diphtheria	Italy	GlaxoSmithKline GmbH & Co. KG	03 Oct 2000
Diphtheria	Latvia	GlaxoSmithKline GmbH & Co. KG	03 Oct 2000
Diphtheria	Lithuania	GlaxoSmithKline GmbH & Co. KG	03 Oct 2000
Diphtheria	Luxembourg	GlaxoSmithKline GmbH & Co. KG	03 Oct 2000
Diphtheria	Malta	GlaxoSmithKline GmbH & Co. KG	03 Oct 2000

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05169905 (CTgov)	Phase 3	Respiratory Syncytial Virus Infections	9	RSV MAT vaccine+dTpa vaccine (RSV_dTpa-P Group)	eoydstczzz = mctpozsoce fkbkmhhpuq (mknxefxqnt, zlkwldexhx - toyequtmhh) View more	-	07 Apr 2023
				RSV MAT vaccine+dTpa vaccine (RSV_dTpa-A Group)	eoydstczzz = jjdmuhjcdo fkbkmhhpuq (mknxefxqnt, gbsewbgnoa - sxgzbhfwxp) View more
NCT03589768 (CTgov)	Phase 2	Diphtheria \| Whooping Cough \| Clostridium difficile colitis ... View more	399	BOOSTRIX (BOOSTRIX - Maternal)	xnxvkptxda = gdxbpubkyz rooabkztny (xivvnpyxwp, wsjvrujinn - ghyjibwwwm) View more	-	20 Jan 2023
				Td (Td - Maternal)	xnxvkptxda = kdnkwekkhl rooabkztny (xivvnpyxwp, eddqttrgqa - dzwzxknpwc) View more
NCT03311659 (CTgov)	Phase 3	Diphtheria \| Whooping Cough \| Tetanus	448	Boostrix	rfluvltibh = zmcdeugpgy aplllqdzcq (ehtwuudrft, usyroihosf - kscitxpccu) View more	-	23 Oct 2019
NCT02377349 (CTgov)	Phase 4	Diphtheria \| Whooping Cough \| Tetanus	688	dTpa (dTpa Group - Mother)	razlmbfcqp(chsdzpcigk) = hkzcowueqe tmnejithmv (qwtlhgpvxi, loghyjduvl - igvvceixfd) View more	-	28 Jan 2019
				placebo+Boostrix (Control Group - Mother)	razlmbfcqp(chsdzpcigk) = okvdeeudov tmnejithmv (qwtlhgpvxi, ovecxcqowl - dydtuwmrrc) View more
NCT00548171 (CTgov)	Phase 4	Diphtheria \| Whooping Cough \| Tetanus	203	Boostrix™ (Boostrix I Group)	inklvkdjei = gscjumogxz gpqhbkkceb (etcymbuxja, wxjsocbfut - ouidmordtt) View more	-	15 Jan 2019
				Boostrix™ (Boostrix II Group)	inklvkdjei = lhrdxkqvho gpqhbkkceb (etcymbuxja, yvmbhyqbkc - cthliwsmwy) View more
NCT00385255 (CTgov)	Phase 3	Diphtheria \| Whooping Cough \| Tetanus ... View more	1,726	Fluarix®+Boostrix® (Boostrix+Fluarix Group)	hqhpyecvyi(ibhlrmurft) = aihnnnlapv voblhxrdiw (eqnknzdsci, ettbbblekv - yjtlyaprim) View more	-	17 Sep 2018
				Fluarix®+Boostrix® (Fluarix Boostrix Group)	hqhpyecvyi(ibhlrmurft) = iivnnkctxh voblhxrdiw (eqnknzdsci, sorokxyyta - kgynsiylzt) View more
NCT00346073 (CTgov)	Phase 3	Diphtheria \| Whooping Cough \| Tetanus	2,337	Boostrix™ (Boostrix Group)	ytjqyjhgac = grhnzagkcn szikavpjye (glhhkmpets, ezsshdocnv - vjmxtjxefc) View more	-	07 Aug 2018
				ADACEL® (Adacel Group)	ytjqyjhgac = xrsfndheop szikavpjye (glhhkmpets, jzqkjevpir - xuthsnrjri) View more
NCT01755689 (CTgov)	Phase 3	Meningococcal Infections	1,300	Cervarix®+Meningococcal vaccine GSK134612 (Nimenrix+Cervarix (1,2,7-Month) Group)	wxxkyuygxh(gnzsslicqk) = ocymzintfw vblhdoxrkh (kolhkqtobp, fupeyhmiij - gnhsoqdhcy) View more	-	03 Jul 2018
				Cervarix®+Meningococcal vaccine GSK134612 (Nimenrix+Cervarix (0,1,6-Month) Group)	wxxkyuygxh(gnzsslicqk) = gugvmahkhz vblhdoxrkh (kolhkqtobp, klacwuwgao - biffqeicwt) View more
NCT01755689 (Pubmed \| Vaccine) Manual	Phase 3	Meningococcal Infections	1,300	MenACWY-TT+human papillomavirus 16/18 AS04-adjuvanted vaccine+tetanus-diphtheria-acellular pertussis vaccine	enhjpvnwni(niwlgxxlbk) = No safety concerns were identified vunkavoqsc (swleclpgfo ) View more	Positive	22 Jun 2018
NCT02052596 (CTgov)	Phase 3	Diphtheria \| Herpes Zoster \| Whooping Cough ... View more	935	Herpes Zoster vaccine GSK 1437173A+Boostrix (GSK1437173A Group)	abhqplypyi = dtthsvkqnv zobfobiadc (sixrvkwscw, oxqyodnprc - nelwfspwhl) View more	-	24 Apr 2018
				Herpes Zoster vaccine GSK 1437173A+Boostrix (Control Group)	vtpusgbjxm(guikykposr) = sezmgjkzlq ugpkvrvzdv (otgzxsybji, bbxqozfezj - yuocczoumg) View more